文献速递头颈神经PETCTMR

头颈癌监测影像(PET/CT与CT和/或MRI)与死亡率:基于人群的研究

Surveillance Imaging with PET/CT and CT and/or MRI for Head and Neck Cancer and Mortality: A Population-based Study.
PubMed 文献 · Radiology · 2023-01-10

该回顾性人群研究纳入2012至2017年诊断的1004例头颈癌患者,利用州癌症登记、全支付方理赔和医疗机构数据,分析监测影像与死亡率的关系。Cox模型显示,在鳞状细胞癌患者中,监测影像与区域期(HR 0.55)和远处期(HR 0.40)死亡率降低相关,非鳞癌患者也显示死亡率降低(HR 0.19)。PET/CT与鳞癌死亡率降低相关,CT和/或MRI与非鳞癌死亡率降低相关。

要点

  • 对于区域期或远处期头颈鳞癌,监测影像与更低死亡率相关。
  • PET/CT与鳞癌死亡率降低相关。
  • CT和/或MRI与非鳞癌死亡率降低相关。

核心结论

  • 监测影像与区域期或远处期头颈鳞癌患者以及非鳞癌患者的死亡率降低相关。
  • 监测影像的保护性关联在治疗完成后长达2年内观察到。

研究设计与样本

  • 回顾性人群研究,纳入2012年1月至2017年12月诊断的头颈癌患者1004例(平均年龄61岁±12,男性753例),包括鳞癌902例和非鳞癌102例。
  • 使用当前操作术语代码检索监测影像操作,采用Cox比例风险模型估计死亡率的风险比(HR)和95%CI,并调整性别、种族、年龄、保险状态、癌症部位、分期和治疗。

诊断标准与关键数值

  • 在非鳞癌患者中,监测影像与更低死亡率相关(HR 0.19;95%CI 0.04,0.94;P=0.04)。
  • PET/CT与鳞癌患者死亡率降低相关(HR 0.29;95%CI 0.09,0.94;P=0.04)。
  • CT和/或MRI与非鳞癌患者死亡率降低相关(HR 0.11;95%CI 0.01,0.94;P=0.04)。

临床应用与阅片要点

  • 对于区域期或远处期头颈鳞癌患者,监测影像(尤其PET/CT)可能与死亡率降低相关,治疗完成后2年内可考虑监测。
  • 非鳞癌患者监测影像(CT和/或MRI)亦与死亡率降低相关,但证据基于较小样本。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂。
  • 全样本鳞癌分析未显示统计学显著关联。
  • 非鳞癌样本量较小(102例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background To the knowledge of the authors, no strong evidence supports surveillance imaging in patients with head and neck cancer (HNC). Purpose To investigate the association between surveillance imaging and mortality using a population-based study design with statewide cancer registry data, all-payer claims data, and health care facility data. Materials and Methods The retrospective population-based study identified patients with HNC diagnosed between January 2012 and December 2017. Current Procedural Terminology codes were used to search surveillance imaging procedures. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for mortality with adjustment for sex, ethnicity, age, health insurance status, cancer site, stage, and treatment. Results The study identified 1004 patients (mean age, 61 years ± 12 [SD]; 753 men), including 902 patients with squamous cell carcinoma (SCC) HNC and 102 patients with non-SCC. The effect of imaging on mortality among patients with SCC was not statistically significant when the entire sample was analyzed (HR, 0.76; 95% CI: 0.57, 1.02; P = .07). However, in stratified analyses by cancer stage, surveillance imaging was associated with lower mortality among patients with SCC for regionalized cancer stage (HR, 0.55; 95% CI: 0.36, 0.83; P = .005) and distant cancer stage (HR, 0.40; 95% CI: 0.19, 0.83; P = .01). Among patients with non-SCC, surveillance imaging was associated with lower mortality versus no surveillance imaging (HR, 0.19; 95% CI: 0.04, 0.94; P = .04). PET/CT was associated with lower mortality for patients with SCC (HR, 0.29; 95% CI: 0.09, 0.94; P = .04), and CT and/or MRI was associated with lower mortality for patients with non-SCC (HR, 0.11; 95% CI: 0.01, 0.94; P = .04). Conclusion Surveillance imaging was associated with lower mortality among patients with head and neck squamous cell carcinoma with regionalized or distant disease. The surveillance imaging protective association was observed up to 2 years after treatment completion. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Branstetter in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Anzai, Chang, Rowe, et al. Surveillance Imaging with PET/CT and CT and/or MRI for Head and Neck Cancer and Mortality: A Population-based Study. Radiology. 2023. PMID: 36625743. doi:10.1148/radiol.212915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。